Zhang Peize, Cao Weipeng, Ye Taosheng, Deng Guofang
Department of Tuberculosis, The Third People's Hospital of Shenzhen, 518112, Shenzhen, China.
J Clin Tuberc Other Mycobact Dis. 2020 Jan 18;19:100146. doi: 10.1016/j.jctube.2020.100146. eCollection 2020 May.
The treatment of multidrug-resistant tuberculosis (MDR-TB) relies heavily on optimal chemotherapy, but interventional therapies can be adopted as adjuvant treatment to speed up illness control and increase the cure rate. We present a case of a 31-year-old MDR-TB male patient with a massive pulmonary cavity in the right lower lung cured by chemotherapy with a catheter inserted in the cavity as adjuvant treatment. This case illustrated that early interventional therapy increases the treatment success rate for pulmonary MDR-TB patients with empyema and massive cavity without the need of major invasive surgery and consequently preserve lung functions.
耐多药结核病（MDR-TB）的治疗严重依赖于优化的化疗，但介入治疗可作为辅助治疗手段，以加速疾病控制并提高治愈率。我们报告一例31岁的耐多药结核病男性患者，其右下肺有巨大肺空洞，通过在空洞内插入导管进行化疗作为辅助治疗而治愈。该病例表明，早期介入治疗可提高合并脓胸和巨大空洞的耐多药肺结核患者的治疗成功率，而无需进行大型侵入性手术，从而保留肺功能。
